Heparan sulfate proteoglycans in the control of B cell development and the pathogenesis of multiple myeloma

FEBS Journal

Volumn 280, Issue 10, 2013, Pages 2180-2193

  Reijmers, Rogier M ^a,b   Spaargaren, Marcel ^a   Pals, Steven T ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

B cell; drug resistance; heparan sulfate proteoglycan; multiple myeloma; plasma cell

Indexed keywords

APRIL PROTEIN; BORTEZOMIB; CHEMOKINE; CYTOKINE; DEXAMETHASONE; DOXYCYCLINE; GROWTH FACTOR; HEPARAN SULFATE; LENALIDOMIDE; PROTEOHEPARAN SULFATE; STROMAL CELL DERIVED FACTOR 1; SYNDECAN 1;

B LYMPHOCYTE; B LYMPHOCYTE DIFFERENTIATION; BIOSYNTHESIS; BONE MARROW; CELL GROWTH; CELL LINEAGE; CELL MATURATION; CELL SURFACE; CELL SURVIVAL; CHEMICAL MODIFICATION; CHEMOSENSITIVITY; DISEASE CONTROL; DRUG MECHANISM; DRUG TARGETING; EMBRYO DEVELOPMENT; ENZYME MECHANISM; HUMAN; IMMUNOPATHOGENESIS; LYMPHATIC SYSTEM TUMOR; MOLECULAR DOCKING; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; PLASMA CELL; POSTNATAL DEVELOPMENT; PRIORITY JOURNAL; PROTEIN CARBOHYDRATE INTERACTION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; TARGET CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; CELL DIFFERENTIATION; CHEMOKINE CXCL12; DEXAMETHASONE; DOXYCYCLINE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPARAN SULFATE PROTEOGLYCANS; HUMANS; MULTIPLE MYELOMA; N-ACETYLGLUCOSAMINYLTRANSFERASES; SYNDECAN-1; TUMOR MICROENVIRONMENT;

EID: 84877713847     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.12180     Document Type: Review

References (118)

1. Esko JD, &, Lindahl U, (2001) Molecular diversity of heparan sulfate. J Clin Invest 108, 169-173. (Pubitemid 32656238)
2. Esko JD, &, Selleck SB, (2002) Order out of chaos: assembly of ligand binding sites in heparan sulfate. Annu Rev Biochem 71, 435-471. (Pubitemid 34800227)
3. Lindahl U, Kusche-Gullberg M, &, Kjellen L, (1998) Regulated diversity of heparan sulfate. J Biol Chem 273, 24979-24982. (Pubitemid 28443251)
4. Bernfield M, Kokenyesi R, Kato M, Hinkes MT, Spring J, Gallo RL, &, Lose EJ, (1992) Biology of the syndecans: a family of transmembrane heparan sulfate proteoglycans. Annu Rev Cell Biol 8, 365-393. (Pubitemid 23001002)
5. Filmus J, &, Selleck SB, (2001) Glypicans: proteoglycans with a surprise. J Clin Invest 108, 497-501. (Pubitemid 32777726)
6. Cole GJ, &, Halfter W, (1996) Agrin: an extracellular matrix heparan sulfate proteoglycan involved in cell interactions and synaptogenesis. Perspect Dev Neurobiol 3, 359-371. (Pubitemid 126839141)
7. Iozzo RV, Cohen IR, Grassel S, &, Murdoch AD, (1994) The biology of perlecan: the multifaceted heparan sulphate proteoglycan of basement membranes and pericellular matrices. Biochem J 302, 625-639. (Pubitemid 24289294)
8. Andres JL, Ronnstrand L, Cheifetz S, &, Massague J, (1991) Purification of the transforming growth factor-beta (TGF-beta) binding proteoglycan betaglycan. J Biol Chem 266, 23282-23287. (Pubitemid 21908791)
9. van der Voort R, Taher TE, Wielenga VJ, Spaargaren M, Prevo R, Smit L, David G, Hartmann G, Gherardi E, &, Pals ST, (1999) Heparan sulfate-modified CD44 promotes hepatocyte growth factor/scatter factor-induced signal transduction through the receptor tyrosine kinase c-Met. J Biol Chem 274, 6499-6506. (Pubitemid 29111066)
10. Heider KH, Hofmann M, Hors E, van den Berg F, Ponta H, Herrlich P, &, Pals ST, (1993) A human homologue of the rat metastasis-associated variant of CD44 is expressed in colorectal carcinomas and adenomatous polyps. J Cell Biol 120, 227-233.
11. Kato M, Wang H, Bernfield M, Gallagher JT, &, Turnbull JE, (1994) Cell surface syndecan-1 on distinct cell types differs in fine structure and ligand binding of its heparan sulfate chains. J Biol Chem 269, 18881-18890. (Pubitemid 24226202)
12. Bishop JR, Schuksz M, &, Esko JD, (2007) Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature 446, 1030-1037. (Pubitemid 46676065)
13. Beauvais DM, Burbach BJ, &, Rapraeger AC, (2004) The syndecan-1 ectodomain regulates alphavbeta3 integrin activity in human mammary carcinoma cells. J Cell Biol 167, 171-181. (Pubitemid 39363424)
14. Beauvais DM, Ell BJ, McWhorter AR, &, Rapraeger AC, (2009) Syndecan-1 regulates alphavbeta3 and alphavbeta5 integrin activation during angiogenesis and is blocked by synstatin, a novel peptide inhibitor. J Exp Med 206, 691-705.
15. Kramer KL, &, Yost HJ, (2003) Heparan sulfate core proteins in cell-cell signaling. Annu Rev Genet 37, 461-484. (Pubitemid 38043946)
16. Morgan MR, Humphries MJ, &, Bass MD, (2007) Synergistic control of cell adhesion by integrins and syndecans. Nat Rev Mol Cell Biol 8, 957-969. (Pubitemid 350174639)
17. Yoneda A, &, Couchman JR, (2003) Regulation of cytoskeletal organization by syndecan transmembrane proteoglycans. Matrix Biol 22, 25-33. (Pubitemid 36444504)
18. Rapraeger AC, (2000) Syndecan-regulated receptor signaling. J Cell Biol 149, 995-998.
19. Jia J, Maccarana M, Zhang X, Bespalov M, Lindahl U, &, Li JP, (2009) Lack of L-iduronic acid in heparan sulfate affects interaction with growth factors and cell signaling. J Biol Chem 284, 15942-15950.
20. Reijmers RM, Groen RW, Rozemuller H, Kuil A, de Haan-Kramer A, Csikõs T, Martens AC, Spaargaren M, &, Pals ST, (2010) Targeting EXT1 reveals a crucial role for heparan sulfate in the growth of multiple myeloma. Blood 115, 601-604.
21. Reijmers RM, Vondenhoff MF, Roozendaal R, Kuil A, Li JP, Spaargaren M, Pals ST, &, Mebius RE, (2010) Impaired lymphoid organ development in mice lacking the heparan sulfate modifying enzyme glucuronyl C5-epimerase. J Immunol 184, 3656-3664.
22. Lindahl U, &, Li JP, (2009) Interactions between heparan sulfate and proteins-design and functional implications. Int Rev Cell Mol Biol 276, 105-159.
23. Kreuger J, Spillmann D, Li JP, &, Lindahl U, (2006) Interactions between heparan sulfate and proteins: the concept of specificity. J Cell Biol 174, 323-327. (Pubitemid 44156762)
24. Whitelock JM, &, Iozzo RV, (2005) Heparan sulfate: a complex polymer charged with biological activity. Chem Rev 105, 2745-2764. (Pubitemid 41055329)
25. Sarrazin S, Lamanna WC, &, Esko JD, (2011) Heparan sulfate proteoglycans. Cold Spring Harb Perspect Biol 3, a004952, doi: 10.1101/cshperspect.a004952.
26. Zak BM, Crawford BE, &, Esko JD, (2002) Hereditary multiple exostoses and heparan sulfate polymerization. Biochim Biophys Acta 1573, 346-355. (Pubitemid 35335443)
27. Lind T, Tufaro F, McCormick C, Lindahl U, &, Lidholt K, (1998) The putative tumor suppressors EXT1 and EXT2 are glycosyltransferases required for the biosynthesis of heparan sulfate. J Biol Chem 273, 26265-26268. (Pubitemid 28471622)
28. McCormick C, Duncan G, Goutsos KT, &, Tufaro F, (2000) The putative tumor suppressors EXT1 and EXT2 form a stable complex that accumulates in the Golgi apparatus and catalyzes the synthesis of heparan sulfate. Proc Natl Acad Sci USA 97, 668-673. (Pubitemid 30070367)
29. Lin X, Wei G, Shi Z, Dryer L, Esko JD, Wells DE, &, Matzuk MM, (2000) Disruption of gastrulation and heparan sulfate biosynthesis in EXT1-deficient mice. Dev Biol 224, 299-311. (Pubitemid 30661012)
30. Lamanna WC, Frese MA, Balleininger M, &, Dierks T, (2008) Sulf loss influences N-, 2-O-, and 6-O-sulfation of multiple heparan sulfate proteoglycans and modulates fibroblast growth factor signaling. J Biol Chem 283, 27724-27735.
31. Morimoto-Tomita M, Uchimura K, Werb Z, Hemmerich S, &, Rosen SD, (2002) Cloning and characterization of two extracellular heparin-degrading endosulfatases in mice and humans. J Biol Chem 277, 49175-49185. (Pubitemid 36014346)
32. Uchimura K, Morimoto-Tomita M, Bistrup A, Li J, Lyon M, Gallagher J, Werb Z, &, Rosen SD, (2006) HSulf-2, an extracellular endoglucosamine-6- sulfatase, selectively mobilizes heparin-bound growth factors and chemokines: effects on VEGF, FGF-1, and SDF-1. BMC Biochem 7, 2.
33. Hulett MD, Freeman C, Hamdorf BJ, Baker RT, Harris MJ, &, Parish CR, (1999) Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis. Nat Med 5, 803-809. (Pubitemid 29318615)
34. Ilan N, Elkin M, &, Vlodavsky I, (2006) Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol 38, 2018-2039. (Pubitemid 44397619)
35. Vlodavsky I, Ilan N, Naggi A, &, Casu B, (2007) Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate. Curr Pharm Des 13, 2057-2073. (Pubitemid 47044735)
36. Derksen PW, Keehnen RM, Evers LM, van Oers MH, Spaargaren M, &, Pals ST, (2002) Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma. Blood 99, 1405-1410. (Pubitemid 34547098)
37. Li JP, Gong F, Hagner-McWhirter A, Forsberg E, Abrink M, Kisilevsky R, Zhang X, &, Lindahl U, (2003) Targeted disruption of a murine glucuronyl C5-epimerase gene results in heparan sulfate lacking L-iduronic acid and in neonatal lethality. J Biol Chem 278, 28363-28366. (Pubitemid 36935735)
38. Merry CL, Bullock SL, Swan DC, Backen AC, Lyon M, Beddington RS, Wilson VA, &, Gallagher JT, (2001) The molecular phenotype of heparan sulfate in the Hs2st-/- mutant mouse. J Biol Chem 276, 35429-35434.
39. Celie JW, Reijmers RM, Slot EM, Beelen RH, Spaargaren M, Ter Wee PM, Florquin S, &, van den Born J, (2008) Tubulointerstitial heparan sulfate proteoglycan changes in human renal diseases correlate with leukocyte influx and proteinuria. Am J Physiol Renal Physiol 294, F253-F263.
40. Arpin C, Dechanet J, Van Kooten C, Merville P, Grouard G, Briere F, Banchereau J, &, Liu YJ, (1995) Generation of memory B cells and plasma cells in vitro. Science 268, 720-722.
41. Allman DM, Ferguson SE, &, Cancro MP, (1992) Peripheral B cell maturation. I. Immature peripheral B cells in adults are heat-stable antigenhi and exhibit unique signaling characteristics. J Immunol 149, 2533-2540.
42. Allman DM, Ferguson SE, Lentz VM, &, Cancro MP, (1993) Peripheral B cell maturation. II. Heat-stable antigen(hi) splenic B cells are an immature developmental intermediate in the production of long-lived marrow-derived B cells. J Immunol 151, 4431-4444. (Pubitemid 23318496)
43. Sanderson RD, Lalor P, &, Bernfield M, (1989) B lymphocytes express and lose syndecan at specific stages of differentiation. Cell Regul 1, 27-35.
44. Tung JW, Mrazek MD, Yang Y, &, Herzenberg LA, (2006) Phenotypically distinct B cell development pathways map to the three B cell lineages in the mouse. Proc Natl Acad Sci USA 103, 6293-6298.
45. Yamashita Y, Oritani K, Miyoshi EK, Wall R, Bernfield M, &, Kincade PW, (1999) Syndecan-4 is expressed by B lineage lymphocytes and can transmit a signal for formation of dendritic processes. J Immunol 162, 5940-5948. (Pubitemid 29314949)
46. Schebesta A, McManus S, Salvagiotto G, Delogu A, Busslinger GA, &, Busslinger M, (2007) Transcription factor Pax5 activates the chromatin of key genes involved in B cell signaling, adhesion, migration, and immune function. Immunity 27, 49-63. (Pubitemid 47096800)
47. Schebesta M, Pfeffer PL, &, Busslinger M, (2002) Control of pre-BCR signaling by Pax5-dependent activation of the BLNK gene. Immunity 17, 473-485. (Pubitemid 35223536)
48. Rolink A, Streb M, Nishikawa S, &, Melchers F, (1991) The c-kit-encoded tyrosine kinase regulates the proliferation of early pre-B cells. Eur J Immunol 21, 2609-2612.
49. Rolink A, Grawunder U, Winkler TH, Karasuyama H, &, Melchers F, (1994) IL-2 receptor alpha chain (CD25, TAC) expression defines a crucial stage in pre-B cell development. Int Immunol 6, 1257-1264. (Pubitemid 24254130)
50. Borghesi LA, Yamashita Y, &, Kincade PW, (1999) Heparan sulfate proteoglycans mediate interleukin-7-dependent B lymphopoiesis. Blood 93, 140-148. (Pubitemid 29019397)
51. Buono M, Visigalli I, Bergamasco R, Biffi A, &, Cosma MP, (2010) Sulfatase modifying factor 1-mediated fibroblast growth factor signaling primes hematopoietic multilineage development. J Exp Med 207, 1647-1660.
52. Milne CD, Corfe SA, &, Paige CJ, (2008) Heparan sulfate and heparin enhance ERK phosphorylation and mediate preBCR-dependent events during B lymphopoiesis. J Immunol 180, 2839-2847.
53. Reijmers RM, Groen RW, Kuil A, Weijer K, Kimberley FC, Medema JP, van Kuppevelt TH, Li JP, Spaargaren M, &, Pals ST, (2011) Disruption of heparan sulfate proteoglycan conformation perturbs B-cell maturation and APRIL-mediated plasma cell survival. Blood 117, 6162-6171.
54. Duchez S, Pascal V, Cogne N, Jayat-Vignoles C, Julien R, &, Cogne M, (2011) Glycotranscriptome study reveals an enzymatic switch modulating glycosaminoglycan synthesis during B cell development and activation. Eur J Immunol 41, 3632-3644.
55. Garner OB, Yamaguchi Y, Esko JD, &, Videm V, (2008) Small changes in lymphocyte development and activation in mice through tissue-specific alteration of heparan sulphate. Immunology 125, 420-429.
56. Espeli M, Rossi B, Mancini SJ, Roche P, Gauthier L, &, Schiff C, (2006) Initiation of pre-B cell receptor signaling: common and distinctive features in human and mouse. Semin Immunol 18, 56-66. (Pubitemid 43238337)
57. O'Connell FP, Pinkus JL, &, Pinkus GS, (2004) CD138 (syndecan-1), a plasma cell marker immunohistochemical profile in hematopoietic and nonhematopoietic neoplasms. Am J Clin Pathol 121, 254-263. (Pubitemid 38140131)
58. van den Born J, Salmivirta K, Henttinen T, Ostman N, Ishimaru T, Miyaura S, Yoshida K, &, Salmivirta M, (2005) Novel heparan sulfate structures revealed by monoclonal antibodies. J Biol Chem 280, 20516-20523. (Pubitemid 40776752)
59. Jarousse N, Chandran B, &, Coscoy L, (2008) Lack of heparan sulfate expression in B-cell lines: implications for Kaposi's sarcoma-associated herpesvirus and murine gammaherpesvirus 68 infections. J Virol 82, 12591-12597.
60. van der Voort R, Keehnen RM, Beuling EA, Spaargaren M, &, Pals ST, (2000) Regulation of cytokine signaling by B cell antigen receptor and CD40-controlled expression of heparan sulfate proteoglycans. J Exp Med 192, 1115-1124.
61. Gordin M, Tesio M, Cohen S, Gore Y, Lantner F, Leng L, Bucala R, &, Shachar I, (2010) c-Met and its ligand hepatocyte growth factor/scatter factor regulate mature B cell survival in a pathway induced by CD74. J Immunol 185, 2020-2031.
62. Coombe DR, (2008) Biological implications of glycosaminoglycan interactions with haemopoietic cytokines. Immunol Cell Biol 86, 598-607.
63. Bret C, Hose D, Reme T, Sprynski AC, Mahtouk K, Schved JF, Quittet P, Rossi JF, Goldschmidt H, &, Klein B, (2009) Expression of genes encoding for proteins involved in heparan sulphate and chondroitin sulphate chain synthesis and modification in normal and malignant plasma cells. Br J Haematol 145, 350-368.
64. Tokoyoda K, Hauser AE, Nakayama T, &, Radbruch A, (2010) Organization of immunological memory by bone marrow stroma. Nat Rev Immunol 10, 193-200.
65. Podar K, Richardson PG, Hideshima T, Chauhan D, &, Anderson KC, (2007) The malignant clone and the bone-marrow environment. Best Pract Res Clin Haematol 20, 597-612. (Pubitemid 350215375)
66. Tokoyoda K, Egawa T, Sugiyama T, Choi BI, &, Nagasawa T, (2004) Cellular niches controlling B lymphocyte behavior within bone marrow during development. Immunity 20, 707-718. (Pubitemid 38757441)
67. Radbruch A, Muehlinghaus G, Luger EO, Inamine A, Smith KG, Dorner T, &, Hiepe F, (2006) Competence and competition: the challenge of becoming a long-lived plasma cell. Nat Rev Immunol 6, 741-750. (Pubitemid 44453460)
68. Laguri C, Arenzana-Seisdedos F, &, Lortat-Jacob H, (2008) Relationships between glycosaminoglycan and receptor binding sites in chemokines-the CXCL12 example. Carbohydr Res 343, 2018-2023.
69. Rueda P, Balabanian K, Lagane B, Staropoli I, Chow K, Levoye A, Laguri C, Sadir R, Delaunay T, Izquierdo E, et al,. (2008) The CXCL12gamma chemokine displays unprecedented structural and functional properties that make it a paradigm of chemoattractant proteins. PLoS ONE 3, e2543.
70. Hideshima T, Chauhan D, Hayashi T, Podar K, Akiyama M, Gupta D, Richardson P, Munshi N, &, Anderson KC, (2002) The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma. Mol Cancer Ther 1, 539-544.
71. O'Connor BP, Raman VS, Erickson LD, Cook WJ, Weaver LK, Ahonen C, Lin LL, Mantchev GT, Bram RJ, &, Noelle RJ, (2004) BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med 199, 91-98.
72. Belnoue E, Pihlgren M, McGaha TL, Tougne C, Rochat AF, Bossen C, Schneider P, Huard B, Lambert PH, &, Siegrist CA, (2008) APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells. Blood 111, 2755-2764.
73. Kimberley FC, van Bostelen L, Cameron K, Hardenberg G, Marquart JA, Hahne M, &, Medema JP, (2009) The proteoglycan (heparan sulfate proteoglycan) binding domain of APRIL serves as a platform for ligand multimerization and cross-linking. FASEB J 23, 1584-1595.
74. Hendriks J, Planelles L, de Jong-Odding J, Hardenberg G, Pals ST, Hahne M, Spaargaren M, &, Medema JP, (2005) Heparan sulfate proteoglycan binding promotes APRIL-induced tumor cell proliferation. Cell Death Differ 12, 637-648. (Pubitemid 40767166)
75. Ingold K, Zumsteg A, Tardivel A, Huard B, Steiner QG, Cachero TG, Qiang F, Gorelik L, Kalled SL, Acha-Orbea H, et al,. (2005) Identification of proteoglycans as the APRIL-specific binding partners. J Exp Med 201, 1375-1383. (Pubitemid 40664082)
76. Huard B, McKee T, Bosshard C, Durual S, Matthes T, Myit S, Donze O, Frossard C, Chizzolini C, Favre C, et al,. (2008) APRIL secreted by neutrophils binds to heparan sulfate proteoglycans to create plasma cell niches in human mucosa. J Clin Invest 118, 2887-2895.
77. Cassese G, Arce S, Hauser AE, Lehnert K, Moewes B, Mostarac M, Muehlinghaus G, Szyska M, Radbruch A, &, Manz RA, (2003) Plasma cell survival is mediated by synergistic effects of cytokines and adhesion-dependent signals. J Immunol 171, 1684-1690. (Pubitemid 36966450)
78. Van Driel M, Gunthert U, van Kessel AC, Joling P, Stauder R, Lokhorst HM, &, Bloem AC, (2002) CD44 variant isoforms are involved in plasma cell adhesion to bone marrow stromal cells. Leukemia 16, 135-143. (Pubitemid 34105609)
79. Wijdenes J, Vooijs WC, Clément C, Post J, Morard F, Vita N, Laurent P, Sun RX, Klein B, &, Dore JM, (1996) A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1. Br J Haematol 94, 318-323. (Pubitemid 26247990)
80. Stepp MA, Gibson HE, Gala PH, Iglesia DD, Pajoohesh-Ganji A, Pal-Ghosh S, Brown M, Aquino C, Schwartz AM, Goldberger O, et al,. (2002) Defects in keratinocyte activation during wound healing in the syndecan-1-deficient mouse. J Cell Sci 115, 4517-4531. (Pubitemid 36004412)
81. Rops AL, Götte M, Baselmans MH, van den Hoven MJ, Steenbergen EJ, Lensen JF, Wijnhoven TJ, Cevikbas F, van den Heuvel LP, et al,. (2007) Syndecan-1 deficiency aggravates anti-glomerular basement membrane nephritis. Kidney Int 72, 1204-1215. (Pubitemid 350059661)
82. Kumar S, Fonseca R, Ketterling RP, Dispenzieri A, Lacy MQ, Gertz MA, Hayman SR, Buadi FK, Dingli D, Knudson RA, et al,. (2012) Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood 119, 2100-2105.
83. Chng WJ, Glebov O, Bergsagel PL, &, Kuehl WM, (2007) Genetic events in the pathogenesis of multiple myeloma. Best Pract Res Clin Haematol 20, 571-596. (Pubitemid 350215376)
84. Kyle RA, &, Rajkumar SV, (2009) Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 23, 3-9.
85. Raab MS, Podar K, Breitkreutz I, Richardson PG, &, Anderson KC, (2009) Multiple myeloma. Lancet 374, 324-339.
86. Dalton WS, (2003) The tumor microenvironment: focus on myeloma. Cancer Treat Rev 29 (Suppl 1), 11-19. (Pubitemid 36626288)
87. Groen RW, de Rooij MF, Kocemba KA, Reijmers RM, de Haan-Kramer A, Overdijk MB, Aalders L, Rozemuller H, Martens AC, Bergsagel PL, et al,. (2011) N-cadherin-mediated adhesion of multiple myeloma cells inhibits osteoblast differentiation. Haematologica 96, 1653-1661.
88. de Gorter DJ, Reijmers RM, Beuling EA, Naber HP, Kuil A, Kersten MJ, Pals ST, &, Spaargaren M, (2008) The small GTPase Ral mediates SDF-1-induced migration of B cells and multiple myeloma cells. Blood 111, 3364-3372.
89. Derksen PW, de Gorter DJ, Meijer HP, Bende RJ, van Dijk M, Lokhorst HM, Bloem AC, Spaargaren M, &, Pals ST, (2003) The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma. Leukemia 17, 764-774. (Pubitemid 36519374)
90. Derksen PW, Tjin E, Meijer HP, Klok MD, MacGillavry HD, van Oers MH, Lokhorst HM, Bloem AC, Clevers H, Nusse R, et al,. (2004) Illegitimate WNT signaling promotes proliferation of multiple myeloma cells. Proc Natl Acad Sci USA 101, 6122-6127. (Pubitemid 38520538)
91. Tjin EP, Derksen PW, Kataoka H, Spaargaren M, &, Pals ST, (2004) Multiple myeloma cells catalyze hepatocyte growth factor (HGF) activation by secreting the serine protease HGF-activator. Blood 104, 2172-2175. (Pubitemid 39297873)
92. Mahtouk K, Cremer FW, Rème T, Jourdan M, Baudard M, Moreaux J, Requirand G, Fiol G, De Vos J, Moos M, et al,. (2006) Heparan sulphate proteoglycans are essential for the myeloma cell growth activity of EGF-family ligands in multiple myeloma. Oncogene 25, 7180-7191. (Pubitemid 44764187)
93. Mahtouk K, Tjin EP, Spaargaren M, &, Pals ST, (2010) The HGF/MET pathway as target for the treatment of multiple myeloma and B-cell lymphomas. Biochim Biophys Acta 1806, 208-219.
94. Khotskaya YB, Dai Y, Ritchie JP, MacLeod V, Yang Y, Zinn K, &, Sanderson RD, (2009) Syndecan-1 is required for robust growth, vascularization, and metastasis of myeloma tumors in vivo. J Biol Chem 284, 26085-26095.
95. Yang Y, MacLeod V, Dai Y, Khotskaya-Sample Y, Shriver Z, Venkataraman G, Sasisekharan R, Naggi A, Torri G, Casu B, et al,. (2007) The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy. Blood 110, 2041-2048. (Pubitemid 47443921)
96. Yang Y, Yaccoby S, Liu W, Langford JK, Pumphrey CY, Theus A, Epstein J, &, Sanderson RD, (2002) Soluble syndecan-1 promotes growth of myeloma tumors in vivo. Blood 100, 610-617. (Pubitemid 34761126)
97. Moreaux J, Legouffe E, Jourdan E, Quittet P, Rème T, Lugagne C, Moine P, Rossi JF, Klein B, &, Tarte K, (2004) BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 103, 3148-3157. (Pubitemid 38451693)
98. Tai YT, Li XF, Breitkreutz I, Song W, Neri P, Catley L, Podar K, Hideshima T, Chauhan D, Raje N, et al,. (2006) Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Res 66, 6675-6682. (Pubitemid 44085624)
99. Moreaux J, Sprynski AC, Dillon SR, Mahtouk K, Jourdan M, Ythier A, Moine P, Robert N, Jourdan E, Rossi JF, et al,. (2009) APRIL and TACI interact with syndecan-1 on the surface of multiple myeloma cells to form an essential survival loop. Eur J Haematol 83, 119-129.
100. Bischof D, Elsawa SF, Mantchev G, Yoon J, Michels GE, Nilson A, Sutor SL, Platt JL, Ansell SM, von Bulow G, et al,. (2006) Selective activation of TACI by syndecan-2. Blood 107, 3235-3242.
101. Yaccoby S, Pennisi A, Li X, Dillon SR, Zhan F, Barlogie B, &, Shaughnessy JD Jr, (2008) Atacicept (TACI-Ig) inhibits growth of TACI(high) primary myeloma cells in SCID-hu mice and in coculture with osteoclasts. Leukemia 22, 406-413. (Pubitemid 351250547)
102. Dai Y, Yang Y, MacLeod V, Yue X, Rapraeger AC, Shriver Z, Venkataraman G, Sasisekharan R, &, Sanderson RD, (2005) HSulf-1 and HSulf-2 are potent inhibitors of myeloma tumor growth in vivo. J Biol Chem 280, 40066-40073. (Pubitemid 41779141)
103. Groen RW, Noort WA, Raymakers RA, Prins HJ, Aalders L, Hofhuis FM, Moerer P, van Velzen JF, Bloem AC, van Kessel B, et al,. (2012) Reconstructing the human hematopoietic niche in immunodeficient mice: opportunities for studying primary multiple myeloma. Blood 120, e9-e16.
104. Rozemuller H, van der Spek E, Bogers-Boer LH, Zwart MC, Verweij V, Emmelot M, Groen RW, Spaapen R, Bloem AC, Lokhorst HM, et al,. (2008) A bioluminescence imaging based in vivo model for preclinical testing of novel cellular immunotherapy strategies to improve the graft-versus-myeloma effect. Haematologica 93, 1049-1057. (Pubitemid 351957022)
105. Spaapen RM, Groen RW, van den Oudenalder K, Guichelaar T, van Elk M, Aarts-Riemens T, Bloem AC, Storm G, Martens AC, Lokhorst HM, et al,. (2010) Eradication of medullary multiple myeloma by CD4+ cytotoxic human T lymphocytes directed at a single minor histocompatibility antigen. Clin Cancer Res 16, 5481-5488.
106. Kelly T, Miao HQ, Yang Y, Navarro E, Kussie P, Huang Y, MacLeod V, Casciano J, Joseph L, Zhan F, et al,. (2003) High heparanase activity in multiple myeloma is associated with elevated microvessel density. Cancer Res 63, 8749-8756. (Pubitemid 38064053)
107. Mahtouk K, Hose D, Raynaud P, Hundemer M, Jourdan M, Jourdan E, Pantesco V, Baudard M, De Vos J, Larroque M, et al,. (2007) Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma. Blood 109, 4914-4923. (Pubitemid 46827789)
108. Purushothaman A, Uyama T, Kobayashi F, Yamada S, Sugahara K, Rapraeger AC, &, Sanderson RD, (2010) Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis. Blood 115, 2449-2457.
109. Yang Y, Ren Y, Ramani VC, Nan L, Suva LJ, &, Sanderson RD, (2010) Heparanase enhances local and systemic osteolysis in multiple myeloma by upregulating the expression and secretion of RANKL. Cancer Res 70, 8329-8338.
110. Yang Y, Macleod V, Miao HQ, Theus A, Zhan F, Shaughnessy JD Jr, Sawyer J, Li JP, Zcharia E, Vlodavsky I, et al,. (2007) Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis. J Biol Chem 282, 13326-13333. (Pubitemid 47100527)
111. Hideshima T, Mitsiades C, Tonon G, Richardson PG, &, Anderson KC, (2007) Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 7, 585-598. (Pubitemid 47106630)
112. Ritchie JP, Ramani VC, Ren Y, Naggi A, Torri G, Casu B, Penco S, Pisano C, Carminati P, Tortoreto M, et al,. (2011) SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis. Clin Cancer Res 17, 1382-1393.
113. Di Giacomo F, Lewandowski D, Cabannes E, Nancy-Portebois V, Petitou M, Fichelson S, &, Romeo PH, (2012) Heparan sulfate mimetics can efficiently mobilize long-term hematopoietic stem cells. Haematologica 97, 491-499.
114. Bullock SL, Fletcher JM, Beddington RS, &, Wilson VA, (1998) Renal agenesis in mice homozygous for a gene trap mutation in the gene encoding heparan sulfate 2-sulfotransferase. Genes Dev 12, 1894-1906. (Pubitemid 28304341)
115. Ringvall M, Ledin J, Holmborn K, van Kuppevelt T, Ellin F, Eriksson I, Olofsson AM, Kjellen L, &, Forsberg E, (2000) Defective heparan sulfate biosynthesis and neonatal lethality in mice lacking N-deacetylase/N- sulfotransferase-1. J Biol Chem 275, 25926-25930.
116. Lindahl U, (2007) Heparan sulfate-protein interactions-a concept for drug design? Thromb Haemost 98, 109-115. (Pubitemid 47074185)
117. Lyon M, Deakin JA, Mizuno K, Nakamura T, &, Gallagher JT, (1994) Interaction of hepatocyte growth factor with heparan sulfate. Elucidation of the major heparan sulfate structural determinants. J Biol Chem 269, 11216-11223.
118. Ashikari S, Habuchi H, &, Kimata K, (1995) Characterization of heparan sulfate oligosaccharides that bind to hepatocyte growth factor. J Biol Chem 270, 29586-29593.